Composition for resisting human coronavirus

By using the extracellular polysaccharide composition produced by Lactobacillus genus Lactobacillus, the proliferation of human coronavirus in non-immune system cells is inhibited, and the problems of human coronavirus infection and aggravation of symptoms are solved, and the effects of prevention and early recovery are achieved.

CN118973409APending Publication Date: 2024-11-15MEIJI CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380031773.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-20
Filing Date
2023-04-19
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively prevent and alleviate human coronavirus infection and its aggravation of symptoms, especially in the absence of effective solutions in non-pharmacological prevention methods.

Method used

Extracellular polysaccharides produced by Lactobacillus genus Lactobacillus are used as the anti-human coronavirus composition to prevent infection and relieve symptoms by inhibiting the proliferation of human coronavirus in non-immune system cells.

Benefits of technology

By ingesting extracellular polysaccharides produced by Lactobacillus genus Lactobacillus, it can effectively prevent human coronavirus infection, reduce the onset and symptoms caused by infection, and promote early recovery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118973409A_ABST
    Figure CN118973409A_ABST
Patent Text Reader

Abstract

The present invention addresses the problem of providing a non-pharmaceutical composition for resisting human coronavirus, which is capable of preventing human coronavirus infection, onset caused by the infection, and aggravation of symptoms caused by the infection. The composition for resisting human coronavirus according to the present invention contains, as an active ingredient, an extracellular polysaccharide produced by a lactic acid bacterium belonging to the genus Lactobacillus. It is to be specified that the lactic acid bacteria of the genus Lactobacillus are preferably lactic acid bacteria belonging to the species Lactobacillus delbrueckii, particularly preferably Lactobacillus delbrueckii subsp. Bulgaricus OLL1073R-1 (FERM BP-10741).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a composition for resisting human coronavirus. Background Art

[0002] As is known to all, human coronavirus (HCoV) is the pathogen of colds. Such human coronaviruses include HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1, MERS-CoV, which causes severe pneumonia, SARS-CoV, and SARS-CoV2. 10-15% (about 35% during the epidemic period) of colds are caused by HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1, and the peak of their epidemic is mainly observed in winter.

[0003] Prior art literature

[0004] Patent Literature

[0005] Patent Document 1: Japanese Patent Application Publication No. 2005-194259

[0006] Patent Document 2: Japanese Patent Application Publication No. 2005-247757

[0007] Patent Document 3: Japanese Patent Application No. 2011-512319

[0008] Patent Document 4: Japanese Patent Application Publication No. 2012-038451

[0009] Patent Document 5: Japanese Patent Application Publication No. 2018-177740

[0010] Patent Document 6: Japanese Patent Application Publication No. 2021-080187 Summary of the invention

[0011] Problem that the invention aims to solve

[0012] However, in recent years, it is hoped that a method for preventing human coronavirus infection, the onset of disease caused by its infection, and the aggravation of symptoms caused by its infection without relying on drugs as much as possible is provided. The subject of the present invention is to provide a non-drug anti-human coronavirus composition that can prevent human coronavirus infection, the onset of disease caused by its infection, and the aggravation of symptoms caused by its infection.

[0013] Solutions for solving problems

[0014] In order to solve the above-mentioned problem, the present inventors focus on the exopolysaccharide (non-drug material) generated by Lactobacillus lactic acid bacteria, and its anti-human coronavirus effect has been studied in detail. And, as a result, find that the anti-human coronavirus effect can be obtained by absorbing this exopolysaccharide, thereby complete the present invention.

[0015] That is, the present invention is as follows.

[0016] (1) A composition for use against human coronavirus, which contains an exopolysaccharide produced by lactic acid bacteria of the genus Lactobacillus as an active ingredient. It should be noted that the composition for use against human coronavirus may contain only the exopolysaccharide or may contain the exopolysaccharide and other ingredients.

[0017] (2) The anti-human coronavirus composition according to (1), wherein the anti-human coronavirus composition is a composition for inhibiting proliferation of human coronavirus.

[0018] (3) The anti-human coronavirus composition according to (2), wherein the human coronavirus proliferation inhibitory composition is a human coronavirus proliferation inhibitory composition in non-immune system cells.

[0019] (4) The anti-human coronavirus composition according to (3), wherein the non-immune system cells are lung cells.

[0020] (5) The anti-human coronavirus composition according to (1), wherein the anti-human coronavirus composition is a preventive composition for preventing at least any one selected from the group consisting of (a) human coronavirus infection, (b) onset of human coronavirus infection, and (c) aggravation of symptoms caused by human coronavirus infection.

[0021] (6) The anti-human coronavirus composition according to (1), wherein the anti-human coronavirus composition is a composition for early recovery after the onset of disease caused by human coronavirus infection.

[0022] (7) The anti-human coronavirus composition according to (1), wherein the human coronavirus is a respiratory infection type human coronavirus.

[0023] (8) The anti-human coronavirus composition according to (1), wherein the lactic acid bacteria of the genus Lactobacillus belong to the species Lactobacillus delbrueckii.

[0024] (9) The anti-human coronavirus composition according to (8), wherein the lactic acid bacteria of the genus Lactobacillus are Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (FERM BP-10741).

[0025] In addition, the present invention also includes the following inventions.

[0026] (10) A method for improving resistance (immunity) to human coronavirus, comprising administering to an individual a composition containing an exopolysaccharide produced by lactic acid bacteria of the genus Lactobacillus, if necessary.

[0027] (11) A method for improving resistance (immunity) to human coronavirus, comprising improving resistance (immunity) to human coronavirus by administering to a subject an exopolysaccharide produced by lactic acid bacteria of the genus Lactobacillus.

[0028] (12) A method for using exopolysaccharide produced by lactic acid bacteria of the genus Lactobacillus as an anti-human coronavirus agent.

[0029] (13) Use of an exopolysaccharide produced by lactic acid bacteria of the genus Lactobacillus for producing a composition for use against human coronavirus.

[0030] (14) Use of exopolysaccharide produced by lactic acid bacteria of the genus Lactobacillus in the production of a composition for use against human coronavirus.

[0031] (15) An exopolysaccharide produced by lactic acid bacteria of the genus Lactobacillus for use in the production of an anti-human coronavirus composition.

[0032] (16) An exopolysaccharide produced by lactic acid bacteria of the genus Lactobacillus, for use as an anti-human coronavirus agent.

[0033] (17) A method for producing an anti-human coronavirus composition by supplying a milk raw material to lactic acid bacteria of the genus Lactobacillus.

[0034] Effects of the Invention

[0035] According to the present invention, human coronavirus infection, the onset of the disease caused by the infection, and the aggravation of symptoms caused by the infection can be prevented by ingesting exopolysaccharide (non-drug) produced by lactic acid bacteria of the genus Lactobacillus. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 The bar graph shows the virus titer of human coronavirus (HCoV-229E) in human fetal lung fibroblast cell line MRC-5 3 days, 5 days, and 7 days after infection in Example 1 and Comparative Example 1. DETAILED DESCRIPTION

[0037] The anti-human coronavirus composition of the embodiment of the present invention contains an exopolysaccharide produced by lactic acid bacteria of the genus Lactobacillus. It should be noted that the exopolysaccharide is preferably an exopolysaccharide produced by Lactobacillus delbrueckii, more preferably an exopolysaccharide produced by Lactobacillus delbrueckii subsp.bulgaricus, and particularly preferably an exopolysaccharide produced by Lactobacillus delbrueckii subsp.bulgaricus OLL1073R-1 (Deposit Number: FERM BP-10741). These exopolysaccharides are not particularly limited as long as they have the target effect, and the exopolysaccharides produced by fermenting milk are preferably used. The exopolysaccharide used in the embodiment of the present invention can be one or a combination of two or more.

[0038] It should be noted that, here, the exopolysaccharide acts as an effective ingredient against human coronavirus. In addition, the exopolysaccharide includes phosphorylated polysaccharides. In addition, the exopolysaccharide may contain non-phosphorylated polysaccharides, and non-phosphorylated polysaccharides do not include sulfated polysaccharides. In addition, the anti-human coronavirus composition is particularly effective for respiratory infection type human coronavirus. It should be noted that human coronavirus is a negative single-stranded RNA virus with an envelope, which mainly infects the upper respiratory tract. Coronavirus belongs to the family Coronaviridae of the order Nidovirales in virus taxonomy. The characteristic of the Coronaviridae family is that it is an enveloped virus with the longest viral genome length among RNA viruses, and as the skeleton of the basic genetic structure of coronavirus, 16 non-structural proteins and 4 structural proteins are encoded in the gene. The structural proteins are spike protein, envelope, matrix, and nucleocapsid, which constitute virus particles, and a viral genome of up to 30kb is encapsulated in virus particles with a diameter of 80 to 160nm (reference 1).

[0039] Reference 1: [Virus Vol. 70 No. 1, pp. 29-36, 2020] 1. The basis of coronaviruses Kamiya Wataru Gunma University Graduate School of Medicine, Department of Biological Defense

[0040] The anti-human coronavirus composition may contain only exopolysaccharide or may contain exopolysaccharide and other components.

[0041] In addition, methods for preparing the anti-human coronavirus composition include, for example: (a) culturing Lactobacillus lactic acid bacteria in a milk culture medium and using the milk culture as an anti-human coronavirus composition; (b) drying or concentrating the aforementioned milk culture and adding the resulting substance to food, etc. and using it as an anti-human coronavirus composition; (c) extracting extracellular polysaccharides from the aforementioned milk culture and using it as an anti-human coronavirus composition; (d) using Lactobacillus lactic acid bacteria to prepare fermented milk and using the fermented milk as an anti-human coronavirus composition, etc.

[0042] When the composition for anti-human coronavirus is prepared in the form of fermented milk, the composition for anti-human coronavirus can be easily ingested in the form of food and drink. In addition, fermented milk has a long history of consumption and is highly safe, so there is no need to worry about side effects, so the ingestor can safely ingest the composition for anti-human coronavirus. As a method for preparing fermented milk, for example, "after sterilizing and cooling the raw milk, adding a lactic acid bacteria starter containing the above-mentioned lactobacillus lactic acid bacteria to the raw milk, and fermenting the raw milk with the added lactic acid bacteria starter at a fermentation temperature and fermentation time that can make the raw milk to which the lactic acid bacteria starter is added reach a prescribed lactic acid acidity" can be cited. Extracellular polysaccharides are produced by lactobacillus lactic acid bacteria during fermentation. In this method, the lactic acid acidity is, for example, 0.6 to 1.2. It should be noted that the lactic acid acidity is preferably 0.6 to 0.8. In addition, the fermentation temperature is, for example, 40 to 45°C. In addition, the fermentation time is, for example, 2 to 12 hours. It should be noted that the fermentation time is preferably 3 to 8 hours.

[0043] It should be noted that, in the embodiment of the present invention, the anti-human coronavirus composition can inhibit the proliferation of human coronavirus in non-immune system cells, and therefore can also be referred to as a composition for inhibiting the proliferation of human coronavirus in non-immune system cells. Here, non-immune system cells are, for example, lung cells.

[0044] In addition, in an embodiment of the present invention, the anti-human coronavirus composition can: (a) prevent human coronavirus infection, (b) prevent the onset of human coronavirus infection, or (c) prevent the aggravation of symptoms caused by human coronavirus infection, and therefore can also be referred to as a composition for preventing human coronavirus infection, a composition for preventing the onset of human coronavirus infection, and a composition for preventing the aggravation of human coronavirus infection.

[0045] In addition, in an embodiment of the present invention, the anti-human coronavirus composition can achieve early recovery after the onset of human coronavirus infection, and therefore can also be referred to as a composition for early recovery after the onset of human coronavirus infection or a composition for promoting recovery after human coronavirus infection.

[0046] "Lactobacillus lactic acid bacteria" in the present invention is a general term for all bacteria identified as Lactobacillus lactic acid bacteria in taxonomy, and is not limited by species, strains, etc. It should be noted that Lactobacillus lactic acid bacteria are sometimes divided into any of plant origin and animal origin according to their source, and the present invention can use any of plant-derived lactic acid bacteria and animal-derived lactic acid bacteria. The strain of Lactobacillus lactic acid bacteria of the present invention is preferably one or more strains of Lactobacillus lactic acid bacteria that can prepare fermented milk (such as yogurt, etc.) with a long history of consumption. It should be noted that the Lactobacillus lactic acid bacteria of an embodiment of the present invention are preferably lactic acid bacteria belonging to Lactobacillus delbrueckii and Lactobacillus delbrueckii subsp. bulgaricus, and are particularly preferably "Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (Deposit Number: FERM BP-10741)" or its derivatives or mutants.

[0047] Sequence number 1 shown in the following sequence listing shows the base sequence (sometimes also referred to as "nucleotide sequence") of the V1 to V3 region of the 16S rRNA gene of Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (corresponding to the base sequence at positions 34 to 535 in the full-length sequence of the 16S rRNA gene).

[0048] (Sequence Listing)

[0049] <16S rRNA gene (SEQ ID NO. 1)>

[0050] GCTGGCGGCGTGCCTAATACATGCAAGTCGAGCGAGCTGAATTCAAAGATYCCTTCGGGRTGATTTGTTGGACGCTAGCGGCGGATGGGTGAGTAACACGTGGGCAATCTGCCCTAAAGACTGGG ATACCACTTGGAAACAGGTGCTAATACCGGATAACAACATGAATCGCATGATTCAAGTTTGAAAGGCGGCGYAAGCTGTCACTTTAGGATGAGCCCGCGGCGCATTAGCTAGTTGGTGGGGTAAAG GCCTACCAAGGCAATGATGCGTAGCCGAGTTGAGAGACTGATCGGCCACATTGGGACTGAGACACGGCCCAAACTCCTACGGGAGGCAGCAGTAGGGAATCTTCCACAATGGACGCAAGTCTGAT GGAGCAACGCCGCGTGAGTGAAGAAGGTTTTCGGATCGTAAAGCTCTGTTGTTGGTGAAGAAGGATAGAGGCAGTAACTGGTCTTTTTGACGGTAATCAACCAGAAAGTCACGGCTAACTACGT

[0051] In addition, " Lactobacillus lactic acid bacteria " in the present invention preferably has polysaccharide productivity. In addition, its polysaccharide is preferably a polysaccharide with galactose and glucose as constituent sugars and containing phosphorus. As this Lactobacillus lactic acid bacteria, preferably there is a 16S rRNA gene with a sequence homology of more than 95% to the base sequence of the sequence number 1 of the above-mentioned sequence table (that is, all or a characteristic part of the sequence of the 16S rRNA gene (V1 region, V2 region, V3 region or all or a part of V1 region, V2 region and V3 region, or a part comprising V1 region, V2 region and V3 region, etc.) of the Lactobacillus lactic acid bacteria, more preferably there is a 16S rRNA gene with a sequence homology of more than 98% to the base sequence of the sequence number 1, and further preferably there is a 16S rRNA gene with a sequence homology of more than 99% to the base sequence of the sequence number 1.

[0052] In addition, a strain having the same mycological properties as Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 can also be used. The mycological properties thereof are as follows.

[0053] (1) Morphological characteristics

[0054] Cell shape: Bacillus

[0055] Sportiness: None

[0056] Presence of spores: None

[0057] Gram staining: positive

[0058] (2) Growth status on culture medium

[0059] The strain was spread on a BL agar medium (Eiken Chemical) plate and cultured at 37°C for 48 hours using the steel wool method, showing an opaque, rough colony morphology.

[0060] (3) Physiological characteristics

[0061] Nitrate reduction: negative

[0062] Indole production: negative

[0063] Gelatin liquefaction: negative

[0064] Catalase: Negative

[0065] Attitude towards oxygen: Facultative anaerobic

[0066] D(-) lactic acid is produced from glucose through homolactic fermentation. No gas is produced. Growth in BL liquid medium at 10°C is negative and growth at 45°C is positive.

[0067] Arginine degradation: negative

[0068] Gas production from malic acid: Negative

[0069] Decomposition of various carbohydrates (positive +, negative -)

[0070] Arabinose-

[0071] Xylose-

[0072] Rhamnose-

[0073] Ribose-

[0074] Glucose+

[0075] Mannose+

[0076] Fructose+

[0077] Galactose-

[0078] sucrose-

[0079] maltose-

[0080] Cellobiose-

[0081] Lactose+

[0082] Trehalose-

[0083] Melibiose-

[0084] Raffinose-

[0085] Melezitose-

[0086] dextrin-

[0087] starch-

[0088] Glycogen-

[0089] Inulin-

[0090] Mannitol-

[0091] Sorbitol-

[0092] Inositol-

[0093] Esculin-

[0094] Salicin-

[0095] (4) Polysaccharide productivity

[0096] As described above, Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 has the ability to produce polysaccharides, and has the characteristic of producing polysaccharides containing galactose and glucose as constituent sugars and containing phosphorus outside the cell.

[0097] In addition, as lactic acid bacteria fermentation agent, from the viewpoint of production efficiency and hobby, preferably Streptococcus lactic acid bacteria or thermophilic streptococcus (Streptococcus thermophilus) are used in combination with Lactobacillus lactic acid bacteria. And then, when Lactobacillus lactic acid bacteria is Lactobacillus delbrueckii subsp.bulgaricus OLL1073R-1 (preservation number: FERM BP-10741), thermophilic bacteria is more preferably thermophilic streptococcus 1131, thermophilic streptococcus OLS3059. And then, for the purpose of being a lactic acid bacteria fermentation agent or imparting functionality, fermentation microorganisms such as lactic acid bacteria, lactococcus, bifidobacterium, yeast, etc., except that Lactobacillus lactic acid bacteria and Streptococcus lactic acid bacteria can also be added.

[0098] Here, "Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1" is deposited at the Patent Organism Depository of the Independent Administrative Institution for Evaluation of Products and Technology (Room 120, 2-5-8, Kazusa Kamata, Kisarazu City, Chiba Prefecture, Japan) with the deposit number FERM BP-10741 (deposit date: November 29, 2006). In addition, "Streptococcus thermophilus OLS3059" is deposited at the Patent Organism Depository of the Independent Administrative Institution for Evaluation of Products and Technology (Room 120, 2-5-8, Kazusa Kamata, Kisarazu City, Chiba Prefecture, Japan) with the deposit number FERM BP-10740 (deposit date: November 29, 2006). Streptococcus thermophilus 1131 can be obtained from Meiji Bulgarian Yogurt "LB81" manufactured by Meiji Co., Ltd.

[0099] "Fermented milk" in the embodiment of the present invention refers to a substance obtained by fermenting milk, and includes, for example, "fermented milk", "lactic acid bacteria beverage", "milk beverage", "natural cheese" and the like defined in the provincial ordinance on the ingredient standards of milk and dairy products (milk, etc. provincial ordinance), but is not limited to these. For example, fermented milk refers to "fermented milk" defined in the provincial ordinance on milk, etc., that is, raw milk, cow's milk, special cow's milk, raw goat's milk, sterilized goat's milk, raw sheep's milk, ingredient-adjusted cow's milk, low-fat cow's milk, fat-free cow's milk and processed milk, or milk containing equal to or more non-fat milk solids, etc., fermented with lactic acid bacteria or yeast to form a solid (hard type), paste (soft type) or liquid (beverage type), or frozen, but is not limited to this. In the fermented milk according to the embodiment of the present invention, the concentration range of the non-fat milk solids component is, for example, preferably in the range of 4.0 mass % or more and 12.0 mass % or less, more preferably in the range of 6.0 mass % or more and 10.0 mass % or less, and further preferably in the range of 7.0 mass % or more and 9.0 mass % or less. In addition, the concentration of the milk fat component is, for example, preferably in the range of 0.2 mass % or more and 4.0 mass % or less, more preferably in the range of 0.3 mass % or more and 3.0 mass % or less, and further preferably in the range of 0.4 mass % or more and 2.0 mass % or less.

[0100] In addition, in an embodiment of the present invention, the daily intake of extracellular polysaccharide is preferably 100 μg or more, more preferably 500 μg or more, further preferably 1.0 mg or more, and particularly preferably 2.0 mg or more. It should be noted that the upper limit of the daily intake of extracellular polysaccharide is not particularly limited, for example, preferably 200 mg, more preferably 100 mg, further preferably 70 mg, further preferably 35 mg, further preferably 30 mg, and particularly preferably 8.0 mg.

[0101] Yogurt can be cited as a typical example of fermented milk. The international standard defined by the Food and Agriculture Organization (FAO) / World Health Organization (WHO) stipulates that "the product called yogurt is made from dairy products such as milk and skimmed milk powder by lactic acid fermentation of two bacteria, Streptococcus thermophilus and Lactobacillus delbrueckii subspecies bulgaricus, and a large amount of live bacteria of the above two bacteria are present in the final product." In the present invention, "yogurt" includes the yogurt defined by the above FAO / WHO. The yogurt includes, for example, plain yogurt, hard yogurt (set yogurt), soft yogurt, yogurt drinks, etc. In the present invention, yogurt drinks are particularly preferred from the viewpoint of easy intake.

[0102] By making the anti-human coronavirus composition of the embodiment of the present invention into a packaged form in an amount suitable for one intake, the anti-human coronavirus composition of the embodiment of the present invention can be appropriately and easily ingested, which is preferred from the perspective of usability. The amount suitable for one intake depends on the degree of infection, the progression of symptoms, etc., and there are individual differences and deviations. When the anti-human coronavirus composition is, for example, fermented milk with a non-fat milk solid content of 8.0% by mass, it is preferably within the range of 10 mL or more and 1000 mL or less each time, more preferably within the range of 30 mL or more and 500 mL or less, further preferably within the range of 50 mL or more and 200 mL or less, preferably 80 mL or more and 120 mL or less. Alternatively, it is preferably within the range of 10 g or more and 1000 g or less each time, preferably within the range of 30 g or more and 500 g or less, preferably within the range of 50 g or more and 200 g or less, more preferably within the range of 80 g or more and 150 g or less, and further preferably within the range of 100 g or more and 120 g or less.

[0103] In the embodiment of the present invention, "one package form" includes all forms, such as conventional packaging methods such as a container with a lid, a bottle with a lid, an independent bag, a pouch, a tube, etc. In the embodiment of the present invention, by recording the use, efficacy, and method of ingestion of the anti-human coronavirus composition of the embodiment of the present invention on each independent package or a package containing multiple independent packages, and / or enclosing an article recording the instructions, etc., and / or separately posting an article recording the instructions such as an instruction manual, etc., its use can be clarified.

[0104] From the viewpoint of improving the anti-human coronavirus effect, it is preferred to continuously ingest the anti-human coronavirus composition of the embodiment of the present invention for more than 3 days, preferably for more than 5 days, preferably for more than 1 week, preferably for more than 2 weeks, preferably for more than 4 weeks, more preferably for more than 6 weeks, further preferably for more than 8 weeks, further preferably for more than 10 weeks, further preferably for more than 12 weeks, further for more than 24 weeks, and particularly preferably for more than 36 weeks. It should be noted that when the anti-human coronavirus composition of the embodiment of the present invention is fermented milk, the anti-human coronavirus composition has a long history of consumption and can be safely ingested, so the upper limit of the intake period is not particularly limited, and can be permanently continued. If an upper limit must be set, for example, it is less than 60 weeks. It should be noted that the upper limit can be set to less than 120 weeks, less than 100 weeks, or less than 80 weeks, depending on the degree of infection, the progression of symptoms, etc.

[0105] By taking the anti-human coronavirus composition of the embodiment of the present invention, it is possible to achieve anti-human coronavirus, inhibit the proliferation of human coronavirus in non-immune system cells, prevent human coronavirus infection, prevent the onset of human coronavirus infection, prevent the symptoms of human coronavirus infection from worsening, and recover early after the onset of human coronavirus infection. It should be noted that, as a mode of intake, oral intake is preferred.

[0106] For viral infections, the anti-human coronavirus composition of the embodiment of the present invention can be used for prevention before the onset of disease, and can be used for treatment after the onset of disease. In addition, it can be used to suppress the onset of disease during the period of suspected infection. In the embodiments performed by the present inventors, the extracellular polysaccharide of lactic acid bacteria of the genus Lactobacillus showed an effect at a relatively early stage after being added to the target cells. Therefore, when suspected infection occurs, by immediately taking the anti-human coronavirus composition of the embodiment of the present invention, the proliferation of human coronaviruses and the onset of disease can be suppressed from the early stage of infection, so it can also be expected that even if infected and morbid, symptoms can be alleviated.

[0107] In addition, it is preferred that the anti-human coronavirus composition of the embodiment of the present invention is marked with instructions such as its use, efficacy, function, type of active ingredient, and method of use. The "labeling" referred to here includes all labels used to inform the user of the above-mentioned effect description. The labeling can be a label that can be imagined and analogized to the above-mentioned labeling content, and may include all labels that are completely unrestricted, such as the purpose of the labeling, the content of the labeling, and the object and medium for labeling. For example, the above-mentioned instructions can be marked on the packaging and container of the product, the above-mentioned instructions can be marked on the advertisement, price list or transaction document related to the product and displayed or published, or information with these contents can be provided through electromagnetic methods (such as the Internet).

[0108] The product packaged with the anti-human coronavirus composition of an embodiment of the present invention preferably has labels such as "anti-human coronavirus", "for inhibiting the proliferation of human coronavirus", "for inhibiting the proliferation of human coronavirus in non-immune system cells", "for preventing human coronavirus infection", "for preventing the onset of human coronavirus infection", "for preventing the aggravation of human coronavirus infection symptoms", and "for early recovery after the onset of human coronavirus infection".

[0109] It should be noted that the sentences used for the above indications are not limited to the above examples, and can also be sentences with the same meaning as such meanings. As such sentences, for example, for the needer, various sentences such as "improving resistance to human coronavirus", "maintaining resistance to human coronavirus", "avoiding resistance reduction to human coronavirus", "suppressing the proliferation of human coronavirus", "suppressing the proliferation of human coronavirus in non-immune system cells", "preventing human coronavirus infection", "preventing the onset of human coronavirus infection", "preventing the aggravation of symptoms caused by human coronavirus infection", "recovering the body early after the onset of human coronavirus infection" are all acceptable.

[0110] It should be noted that the above-mentioned anti-human coronavirus composition can be in the form of special purpose food, comprehensive nutritional food, nutritional supplement food, specific health food, functional labeled food, processed food, etc. In addition, the anti-human coronavirus composition and exopolysaccharide can be formulated in beverages other than yogurt drinks, liquid food and other compositions.

[0111] The present invention will be described in more detail below based on examples and comparative examples. It should be noted that the examples do not limit the present invention.

[0112] [Example 1]

[0113] 1. Preparation of Extracellular Polysaccharide

[0114] In a 10% by mass skim milk powder medium, Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 was cultured at 37°C for 18 hours to obtain a culture. Then, trichloroacetic acid was added to the culture in a manner to achieve a final concentration of 10% by mass to remove denatured proteins from the culture. Then, cold ethanol was added to the culture after the denatured proteins were removed, and the culture was then left to stand at 4°C until the next day, resulting in a precipitate containing exopolysaccharides (hereinafter sometimes referred to as "EPS"). Next, the precipitate was dialyzed against MilliQ water using a dialysis membrane (molecular weight fraction 6,000 to 8,000) to obtain a dialysate, and the nucleic acids and proteins in the dialysate were enzymatically hydrolyzed, and ethanol was added to the dialysate again to obtain a precipitate. Then, the precipitate was dissolved in MilliQ water and dialyzed again, and then the dialysate was freeze-dried to obtain the target EPS.

[0115] 2. Anti-human coronavirus test

[0116] (1) Human coronavirus infection treatment of human fetal lung fibroblast cell lines

[0117] Human fetal lung fibroblast cell line MRC-5 was seeded in 25 cm 2 The human fetal lung fibroblast cell line MRC-5 was cultured in Igor's minimum essential medium until subconfluent. Then, the culture medium was removed from the culture flask, and the cell surface of the subconfluent human fetal lung fibroblast cell line MRC-5 was washed once with phosphate-buffered saline, and then the human fetal lung fibroblast cell line MRC-5 was inoculated with a liquid containing human coronavirus (HCoV-229E) at a concentration of infection multiplicity (MOI) = 0.1. After inoculation with the liquid containing human coronavirus (HCoV-229E), the human coronavirus (HCoV-229E) was cultured at 34°C for 1 hour, and then the inoculated liquid containing human coronavirus (HCoV-229E) was removed, and the cell surface of the human fetal lung fibroblast cell line MRC-5 was washed only once with phosphate-buffered saline. Then, 5 mL of 200 μg / mL EPS solution was added to the human fetal lung fibroblast cell line MRC-5, and the human fetal lung fibroblast cell line MRC-5 was cultured at 34°C. Then, the cell culture supernatant was collected after 3 days, 5 days, and 7 days from the start of the culture. Hereinafter, for convenience of description, the cell culture supernatant after 3 days from the start of the culture is referred to as "3-day cell culture supernatant", the cell culture supernatant after 5 days from the start of the culture is referred to as "5-day cell culture supernatant", and the cell culture supernatant after 7 days from the start of the culture is referred to as "7-day cell culture supernatant".

[0118] (2) Determination of the titer of human coronavirus

[0119] First, the above-mentioned 3-day cell culture supernatant, 5-day cell culture supernatant, and 7-day cell culture supernatant are respectively diluted stepwise, and various dilutions are prepared for the 3-day cell culture supernatant, 5-day cell culture supernatant, and 7-day cell culture supernatant. Then, human fetal lung fibroblast cell line MRC-5 is seeded in a 96-well plate, and the human fetal lung fibroblast cell line MRC-5 is cultured to subconfluence. Next, the culture medium is removed from the 96-well plate, and various dilutions of the 3-day cell culture supernatant, 5-day cell culture supernatant, and 7-day cell culture supernatant are inoculated with N=4 for the human fetal lung fibroblast cell line MRC-5, and the human fetal lung fibroblast cell line MRC-5 is cultured at 34°C. The human fetal lung fibroblast cell line MRC-5 inoculated with the cell culture supernatant after 3 days, 5 days and 7 days, was observed, and the number of wells where cell degeneration was observed was measured, and the 50% tissue culture cell infection rate (TCID50) was calculated by the Behrens-Karber method. Finally, the virus titer (TCID50 / mL) was calculated from the 50% tissue culture cell infection rate to obtain Figure 1 The results shown. According to the results, the virus titer of the human fetal lung fibroblast cell line MRC-5 inoculated with the cell culture supernatant after 3 days and the cell culture supernatant after 5 days was almost the same, and the virus titer of the human fetal lung fibroblast cell line MRC-5 inoculated with the cell culture supernatant after 7 days was about 3 times that of the human fetal lung fibroblast cell line MRC-5.

[0120] (Comparative Example 1)

[0121] The EPS-containing liquid was replaced with Eagle's minimum essential medium. The cell culture supernatant after 3 days, the cell culture supernatant after 5 days, and the cell culture supernatant after 7 days were obtained in the same manner as in Example 1. The virus titer of the human fetal lung fibroblast cell line MRC-5 was determined in the same manner as in Example 1. As a result, Figure 1 The results shown. According to the results, the virus titers of the human fetal lung fibroblast cell line MRC-5 inoculated with the cell culture supernatant after 3 days and the cell culture supernatant after 5 days were almost the same, and the virus titer of the human fetal lung fibroblast cell line MRC-5 inoculated with the cell culture supernatant after 7 days was about 3 times that of the human fetal lung fibroblast cell line MRC-5. When compared with the virus titers of Example 1, the virus titers of each virus were as high as 3 times that of them.

[0122] (summary)

[0123] According to the results shown in Example 1 and the results shown in the comparative example, by adding EPS to the human fetal lung fibroblast strain MRC-5 infected with human coronavirus (HCoV-229E) and culturing, the amount of human coronavirus (HCoV-229E) released into the culture supernatant of the human fetal lung fibroblast strain MRC-5 is reduced, that is, the proliferation of human coronavirus (HCoV-229E) is inhibited. The human fetal lung fibroblast strain MRC-5 is a non-immune system cell, and the immune response during infection is weak compared to immune system cells. It is believed that the inhibition of viral proliferation in the organism is very helpful to the function of immune system cells. In addition, EPS inhibits the proliferation of viruses in the human fetal lung fibroblast strain MRC-5 as a non-immune system cell. This is a surprising result.

[0124] In addition, coronaviruses usually invade biological cells and proliferate while releasing RNA required for proliferation in cells. Then, a large number of coronaviruses that have proliferated are further released from cells infected with coronaviruses, causing infection in other cells until the disease occurs. In addition, the severity of viral infections is related to the amount of virus that proliferates in the body. Therefore, by inhibiting the proliferation of viruses in cells, the spread of infection between cells can be inhibited, and it can be expected to prevent the onset of coronavirus infection, prevent the aggravation of symptoms caused by coronavirus infection, or promote early recovery after the onset of human coronavirus infection.

[0125] In addition, pneumonia and other lung infections occur when respiratory infection viruses such as coronaviruses infect the lungs and multiply there, causing damage to the lungs. Therefore, by inhibiting the proliferation of coronaviruses in lung cells, it is expected that pneumonia and other lung infections caused by coronaviruses can be prevented.

[0126] Industrial Applicability

[0127] The anti-human coronavirus composition of the present invention is a non-drug composition that can prevent human coronavirus infection, the onset of disease caused by the infection, and the aggravation of symptoms caused by the infection. It is expected that this effect will also be exerted on new human coronaviruses such as MERS-CoV, SARS-CoV, and SARS-CoV2.

[0128] Accession number

[0129] FERM BP-10741

[0130] FERM BP-10740

Claims

1. A composition for use against human coronavirus, comprising an exopolysaccharide produced by lactic acid bacteria of the genus Lactobacillus as an active ingredient.

2. The anti-human coronavirus composition according to claim 1, wherein The above-mentioned anti-human coronavirus composition is a composition for inhibiting the proliferation of human coronavirus.

3. The anti-human coronavirus composition according to claim 2, wherein The above-mentioned composition for inhibiting the proliferation of human coronavirus is a composition for inhibiting the proliferation of human coronavirus in non-immune system cells.

4. The anti-human coronavirus composition according to claim 3, wherein The above-mentioned non-immune system cells are lung cells.

5. The anti-human coronavirus composition according to claim 1, wherein The anti-human coronavirus composition is a preventive composition for preventing at least any one selected from the group consisting of (a) human coronavirus infection, (b) onset of disease caused by the human coronavirus infection, and (c) aggravation of symptoms caused by the human coronavirus infection.

6. The anti-human coronavirus composition according to claim 1, wherein The above-mentioned anti-human coronavirus composition is a composition for early recovery after the onset of disease caused by human coronavirus infection.

7. The anti-human coronavirus composition according to claim 1, wherein The above-mentioned human coronavirus is a respiratory infection type human coronavirus.

8. The anti-human coronavirus composition according to claim 1, wherein The above-mentioned lactic acid bacteria of the genus Lactobacillus belong to the species Lactobacillus delbrueckii.

9. The anti-human coronavirus composition according to claim 8, wherein The lactic acid bacteria of the genus Lactobacillus are Lactobacillus delbrueckii subsp. bulgaricus OLL1073R-1 (FERM BP-10741).